Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies

Journal of Virological Methods

Volumn 163, Issue 2, 2010, Pages 459-464

  Sirskyj, Danylo ^a   Weltzin, Richard ^a   Golshani, Ashkan ^d   Anderson, David ^a   Bozic, Jasminka ^a   Diaz Mitoma, Francisco ^a,b,c   Azizi, Ali ^a,b,c  

^a Variation Biotechnologies Inc   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CARLETON UNIVERSITY   (Canada)

Author keywords

Antibody; Influenza; Neutralization; Vaccine

Indexed keywords

ANTIBODY CONJUGATE; BIOTIN; FLUVIRAL; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; STREPTAVIDIN; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CELL ASSAY; CELL STRAIN; CONTROLLED STUDY; FERRET; HEMAGGLUTINATION INHIBITION TEST; INCUBATION TIME; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SIGNAL NOISE RATIO; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOTIN; CELL LINE; DOGS; FERRETS; FLUORESCENT DYES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MACACA MULATTA; MALE; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; STREPTAVIDIN;

MACACA; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 73049097456     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.11.014     Document Type: Article

References (33)

1. Abai A.M., Smith L.R., and Wloch M.K. Novel microneutralization assay for HCMV using automated data collection and analysis. J. Immunol. Methods 322 (2007) 82
2. Bavinck V., Bouma A., van B.M., Bos M.E., Stassen E., and Stegeman J.A. The role of backyard poultry flocks in the epidemic of highly pathogenic avian influenza virus (H7N7) in the Netherlands in 2003. Prev. Vet. Med. 88 (2009) 247
3. Brundage J.F., and Shanks G.D. Deaths from bacterial pneumonia during 1918-1919 influenza pandemic. Emerg. Infect. Dis. 14 (2008) 1193
4. Capuaa I., and Alexander D.J. Avian influenza vaccines and vaccination in birds. Vaccine 26 Suppl. 4 (2008) D70-D73
5. Cox N.J., and Subbarao K. Influenza. Lancet 354 (1999) 1277
6. De Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., and Lim W.L. A pandemic warning?. Nature 389 (1997) 554
7. De W.E., and Fouchier R.A. Emerging influenza. J. Clin. Virol. 41 (2008) 1
8. Gardner M.B., and Luciw P.A. Macaque models of human infectious disease. ILAR J. 49 (2008) 220
9. Heller L., Korlof B., Morner J., and Zetterberg B. Serological and prophylactic trials of Asian influenza vaccines in Sweden, 1957. Bull. World Health Organ. 20 (1959) 377
10. Lee M.S., Mahmood K., Adhikary L., August M.J., Cordova J., Cho I., Kemble G., Reisinger K., Walker R.E., and Mendelman P.M. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 23 (2004) 852
11. Michel J.P., Lang P.O., and Baeyens J.P. Flu vaccination policy in old adults: need for harmonization of national public health recommendations throughout Europe. Vaccine 27 (2009) 182
12. Mo C., Yamagata R., Pan A., Reddy J., Hazari N., and Duke G. Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype. J. Virol. Methods 150 (2008) 63
13. Monto A.S. The risk of seasonal and pandemic influenza: prospects for control. Clin. Infect. Dis. 48 Suppl. 1 (2009) S20-S25
14. Myers K.P., Setterquist S.F., Capuano A.W., and Gray G.C. Infection due to 3 avian influenza subtypes in United States veterinarians. Clin. Infect. Dis. 45 (2007) 4
15. Newman F.K., Frey S.E., Blevins T.P., Mandava M., Bonifacio Jr. A., Yan L., and Belshe R.B. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J. Clin. Microbiol. 41 (2003) 3154
16. Noah D.L., Hill H., Hines D., White E.L., and Wolff M.C. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin. Vaccine Immunol. 16 (2009) 558
17. Owen R.E., Yamada E., Thompson C.I., Phillipson L.J., Thompson C., Taylor E., Zambon M., Osborn H.M., Barclay W.S., and Borrow P. Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. J. Virol. 81 (2007) 11170
18. Patterson K.D., and Pyle G.F. The geography and mortality of the 1918 influenza pandemic. Bull. Hist. Med. 65 (1991) 4
19. Pedersen J.C. Hemagglutination-inhibition test for avian influenza virus subtype identification and the detection and quantitation of serum antibodies to the avian influenza virus. Methods Mol. Biol. 436 (2008) 53
20. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoint. Am. J. Hyg. 27 (1938) 493-497
21. Rimmelzwaan G.F., and McElhaney J.E. Correlates of protection: novel generations of influenza vaccines. Vaccine 26 Suppl. 4 (2008) D41-D44
22. Rubino K.L., and Nicholas J.A. A novel, spectrophotometric microneutralization assay for respiratory syncytial virus. J. Virol. Methods 39 (1992) 55
23. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69 (2000) 531
24. Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. 28 (2005) 399
25. Sweet C., and Smith H. Pathogenicity of influenza virus. Microbiol. Rev. 44 (1980) 303
26. Tang J.W., Ngai K.L., and Chan P.K. Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. J. Med. Virol. 80 (2008) 1992
27. Tobita K., Sugiura A., Enomote C., and Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162 (1975) 9
28. Van der Laan J.W., Herberts C., Lambkin-Williams R., Boyers A., Mann A.J., and Oxford J. Animal models in influenza vaccine testing. Expert Rev. Vaccine 7 (2008) 783
29. Van D.P., Oosterhuis-Kafeja F., Van der W.M., Almagor Y., Sharon O., and Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27 (2009) 454
30. Wang S., Parker C., Taaffe J., Solorzano A., Garcia-Sastre A., and Lu S. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26 (2008) 3626
31. Wong G.W., and Leung T.F. Bird flu: lessons from SARS. Paediatr. Respir. Rev. 8 (2007) 171
32. Wood J.M., Gaines-Das R.E., Taylor J., and Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 12 (1994) 167
33. Yang Z.Y., Wei C.J., Kong W.P., Wu L., Xu L., Smith D.F., and Nabel G.J. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317 (2007) 825